Published in N Engl J Med on August 11, 2005
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
miR-214 targets ATF4 to inhibit bone formation. Nat Med (2012) 3.01
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Interpretation of biomarkers of bone metabolism in children: impact of growth velocity and body size in healthy children and chronic disease. J Pediatr (2008) 1.83
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res (2008) 1.82
Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int (2006) 1.79
Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab (2011) 1.74
Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ (2006) 1.74
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res (2013) 1.68
Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell (2010) 1.60
Advanced CT bone imaging in osteoporosis. Rheumatology (Oxford) (2008) 1.58
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (2015) 1.57
Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab (2012) 1.54
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol (2011) 1.43
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
Theoretical implications of the biomechanical fracture threshold. J Bone Miner Res (2008) 1.16
Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2013) 1.10
Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int (2012) 1.08
Identify fracture-critical regions inside the proximal femur using statistical parametric mapping. Bone (2008) 1.07
Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosis. Curr Osteoporos Rep (2013) 1.06
Reversing bone loss by directing mesenchymal stem cells to bone. Stem Cells (2013) 1.06
Treatment of osteoporosis in men. Bone (2012) 1.06
Computational biomechanics of the distal tibia from high-resolution MR and micro-CT images. Bone (2010) 1.04
Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int (2010) 1.04
Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev (2006) 1.01
Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab (2009) 0.99
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res (2009) 0.99
Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab (2009) 0.99
Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab (2014) 0.99
Current and future treatment options in osteoporosis. Eur J Clin Pharmacol (2011) 0.98
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res (2008) 0.98
Noninvasive imaging of bone microarchitecture. Ann N Y Acad Sci (2011) 0.98
Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats. Bone (2014) 0.96
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem (2009) 0.95
Osteoporotic fractures in older adults. Best Pract Res Clin Rheumatol (2006) 0.95
Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab (2008) 0.94
Voxel-based modeling and quantification of the proximal femur using inter-subject registration of quantitative CT images. Bone (2007) 0.93
Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res (2008) 0.92
Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab (2012) 0.92
Gs G protein-coupled receptor signaling in osteoblasts elicits age-dependent effects on bone formation. J Bone Miner Res (2010) 0.92
Correlates of bone quality in older persons. Bone (2006) 0.91
Insights from the conduct of a device trial in older persons: low magnitude mechanical stimulation for musculoskeletal health. Clin Trials (2010) 0.90
Bone biology and anabolic therapies for bone: current status and future prospects. J Bone Metab (2014) 0.90
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int (2007) 0.90
Teriparatide in the management of osteoporosis. Clin Interv Aging (2007) 0.89
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract (2011) 0.88
Assessment of volumetric bone mineral density of the femoral neck in postmenopausal women with and without vertebral fractures using quantitative multi-slice CT. J Zhejiang Univ Sci B (2009) 0.87
Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int (2007) 0.86
Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis. Int J Womens Health (2010) 0.86
Biological agents in management of osteoporosis. Eur J Clin Pharmacol (2014) 0.86
Strategies of spinal fusion on osteoporotic spine. J Korean Neurosurg Soc (2011) 0.86
Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis. Osteoporos Int (2008) 0.85
Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One (2011) 0.85
Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate. Osteoporos Int (2009) 0.84
Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int (2009) 0.84
Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents. J Bone Miner Res (2011) 0.84
Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women. Clin Interv Aging (2007) 0.83
Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag (2006) 0.83
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass. Osteoporos Int (2014) 0.82
The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial. Osteoporos Int (2010) 0.82
Profile of teriparatide in the management of postmenopausal osteoporosis. Int J Womens Health (2010) 0.82
Low-Magnitude Mechanical Stimulation to Improve Bone Density in Persons of Advanced Age: A Randomized, Placebo-Controlled Trial. J Bone Miner Res (2015) 0.81
Bone fracture risk estimation based on image similarity. Bone (2009) 0.81
Updated recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med (2011) 0.81
The effects of aging and electrical stimulation exercise on bone after spinal cord injury. Aging Dis (2013) 0.81
Observations following discontinuation of long-term denosumab therapy. Osteoporos Int (2017) 0.81
The Efficacy of Parathyroid Hormone Analogues in Combination With Bisphosphonates for the Treatment of Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) (2015) 0.81
Activated protein C differentially regulates both viability and differentiation of osteoblasts mediated by bisphosphonates. Exp Mol Med (2013) 0.80
Bone anabolics in osteoporosis: Actuality and perspectives. World J Orthop (2014) 0.80
If you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy. Ther Clin Risk Manag (2011) 0.80
Volumetric femoral BMD, bone geometry, and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int (2015) 0.80
Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database. Osteoporos Int (2016) 0.80
Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int (2012) 0.79
Variability in the measured response of bone to teriparatide. Osteoporos Int (2010) 0.79
Combination and sequential therapy for osteoporosis. N Engl J Med (2005) 0.78
Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. Clin Interv Aging (2006) 0.78
Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. Osteoporos Int (2012) 0.78
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Miner Metab (2009) 0.78
Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest (2016) 0.77
[Cathepsin K antagonists: preclinical and clinical data]. Wien Med Wochenschr (2015) 0.77
Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Alendronate sodium in the management of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Teriparatide treatment of osteoporosis in an HIV-infected man: a case report and literature review. AIDS (2015) 0.76
Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. J Clin Endocrinol Metab (2015) 0.76
Treatment of glucocorticoid-induced osteoporsis. Ther Adv Musculoskelet Dis (2009) 0.76
Alendronate and parathyroid hormone. N Engl J Med (2005) 0.75
Use of combination therapy in the treatment of primary osteoporosis: protocol for a network meta-analysis of randomised trials. BMJ Open (2016) 0.75
Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis. J Natl Med Assoc (2007) 0.75
Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model. Bone (2016) 0.75
The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials. Medicine (Baltimore) (2016) 0.75
1 year of alendronate after 1 year of parathyroid hormone (1-84) treatment increased bone mineral density in osteoporosis. ACP J Club (2006) 0.75
Prevalent and Emerging Therapies for Osteoporosis. Med J Armed Forces India (2011) 0.75
Clinical challenges in the management of osteoporosis. Clin Interv Aging (2008) 0.75
Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate. Calcif Tissue Int (2017) 0.75
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med (2010) 6.47
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA (2011) 4.83
Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem (2002) 4.52
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 3.50
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med (2012) 3.34
Mechanisms of anabolic therapies for osteoporosis. N Engl J Med (2007) 3.33
Bone mineral density and the risk of incident nonspinal fractures in black and white women. JAMA (2005) 3.30
The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. Arch Intern Med (2011) 3.17
Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell (2009) 3.16
Frailty in older men: prevalence, progression, and relationship with mortality. J Am Geriatr Soc (2007) 3.15
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Long-term risk of incident vertebral fractures. JAMA (2007) 3.15
Postmenopausal Osteoporosis. N Engl J Med (2016) 3.04
Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med (2011) 2.96
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom (2008) 2.87
Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care (2002) 2.72
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA (2011) 2.70
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA (2007) 2.62
Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med (2010) 2.60
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone (2008) 2.53
Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol (2011) 2.46
Relationship of changes in physical activity and mortality among older women. JAMA (2003) 2.42
Clinical review: Rare causes of hypercalcemia. J Clin Endocrinol Metab (2005) 2.38
Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab (2004) 2.36
Hip fracture in women without osteoporosis. J Clin Endocrinol Metab (2005) 2.35
Progression of radiographic hip osteoarthritis over eight years in a community sample of elderly white women. Arthritis Rheum (2004) 2.32
Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab (2009) 2.31
Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res (2010) 2.29
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom (2013) 2.29
Reduced renal function and sleep-disordered breathing in community-dwelling elderly men. Sleep Med (2008) 2.26
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial. J Gen Intern Med (2014) 2.20
Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med (2007) 2.17
Diabetes and incidence of functional disability in older women. Diabetes Care (2002) 2.16
The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab (2008) 2.12
Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med (2007) 2.10
Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology (2008) 2.09
Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA (2011) 2.04
High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. J Bone Miner Res (2010) 2.01
Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 1.96
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc (2006) 1.96
Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res (2007) 1.93
Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obesity (Silver Spring) (2010) 1.93
BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res (2006) 1.91
Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab (2006) 1.91
Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J Bone Miner Res (2007) 1.88
Vision impairment and combined vision and hearing impairment predict cognitive and functional decline in older women. J Am Geriatr Soc (2004) 1.88
Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab (2013) 1.88
Differences in bone microarchitecture between postmenopausal Chinese-American and white women. J Bone Miner Res (2011) 1.86
Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res (2014) 1.86
Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc (2004) 1.84
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res (2008) 1.82
Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med (2005) 1.81
Visceral fat is a negative predictor of bone density measures in obese adolescent girls. J Clin Endocrinol Metab (2010) 1.80
The 2011 Dietary Reference Intakes for Calcium and Vitamin D: what dietetics practitioners need to know. J Am Diet Assoc (2011) 1.80
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med (2012) 1.79
Congenic strains of mice for verification and genetic decomposition of quantitative trait loci for femoral bone mineral density. J Bone Miner Res (2003) 1.78
What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res (2005) 1.76
Application of high-resolution skeletal imaging to measurements of volumetric BMD and skeletal microarchitecture in Chinese-American and white women: explanation of a paradox. J Bone Miner Res (2009) 1.76
Prevalence and correlates of periodic limb movements in older women. J Clin Sleep Med (2006) 1.76
Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc (2005) 1.74
Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res (2002) 1.73
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol (2010) 1.72
Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab (2004) 1.71
Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int (2008) 1.71
Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol (2004) 1.71
Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res (2005) 1.70
Vitamin D status and response to Vitamin D(3) in obese vs. non-obese African American children. Obesity (Silver Spring) (2008) 1.69
Mechanical stimulation of mesenchymal stem cell proliferation and differentiation promotes osteogenesis while preventing dietary-induced obesity. J Bone Miner Res (2009) 1.67
Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause (2014) 1.67
Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res (2010) 1.66
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65
Moderate alcohol intake lowers biochemical markers of bone turnover in postmenopausal women. Menopause (2012) 1.63
Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res (2012) 1.63